Clinical trial

A simple breath test could evolve breast cancer diagnostics

The University of Southern California (USC) Norris Comprehensive Cancer Center is actively recruiting for a clinical trial that is researching the effectiveness of a breath test for breast cancer diagnostics. The BreathLink device, manufactured by Menssana Research, Inc., captures a two-minute sample of a patient’s breath and provides immediate results on whether there are indications of breast cancer.

Combined with Mammography, a new breath test could raise the effectiveness of...
Combined with Mammography, a new breath test could raise the effectiveness of detecting breast cancer.
Source: shutterstock/Tomas K

If proven effective, the test would be used in conjunction with mammograms to rule out false-positive tests, sparing patients the pain, cost and anxiety of unnecessary biopsies. “Diagnosing breast cancer requires the utmost vigilance, but we need to temper this vigilance with accuracy to prevent unnecessary testing,” said Linda Hovanessian-Larsen, MD, associate professor of clinical radiology and director of Women’s Imaging at the Keck School of Medicine of USC. Larsen is leading the trial at USC Norris and focuses much of her research to improving the accuracy and efficiency of breast cancer diagnostic techniques. “This kind of technology would be a welcome asset to our field, and we are eager to assess the safety and efficacy of this test.”

BreathLink is a non-invasive testing device that collects, concentrates and analyzes the organic compounds in a patient’s breath sample within minutes. Additionally, test results are uploaded to Menssana’s laboratory in New Jersey. While the test cannot diagnose disease, it can indicate if the patient should undergo further testing, which can save time and money while preventing additional emotional distress. Current research is evaluating the device’s effectiveness in lung cancer, breast cancer, heart transplant rejection, radiation exposure and pulmonary tuberculosis. The device is not yet approved by the Food and Drug Administration.

More information about the trial can be found here.

 

Source: Keck Medicine of USC

25.06.2017

Read all latest stories

Related articles

Technique comparison

Contrast-enhanced digital mammography vs. breast MRI

Contrast-enhanced digital mammography is comparable to breast MRI in evaluating residual breast cancer after neoadjuvant endocrine therapy or chemotherapy, according to the results of a study…

High-grade DCIS detection rates increase in older women

The mammography detection rate of an early-stage but potentially invasive type of breast cancer rises with age, according to a large new study from Germany published online in the journal Radiology.

Research

3D mammography detected 34% more breast cancers in screening

After screening 15 000 women over a period of five years, a major clinical study in Sweden has shown that 3D mammography, or breast tomosynthesis, detects over 30% more cancers compared to…

Related products

Amplification/Detection

Agena Bioscience - MassARRAY Colon Panel

Agena Bioscience GmbH

Displays - Mammo

Barco - Nio 5MP

Barco N.V.

Immunochemistry

Beckman Coulter - phi (Prostate Health Index)

Beckman Coulter, Inc.

Film-screen mammography

Canon - Harmonia

Canon Europa NV

Digital mammography

DMS Imaging - Serenys DR Bym

DMS